-
平臺(tái)編號(hào)：bio-128002
-
國(guó)際編號(hào)：LMBP 12893
-
拉丁屬名： Escherichia coli
-
規(guī)格：K12/
-
用途：BCCM原裝進(jìn)口
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu) 說(shuō)明書(shū)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類(lèi)或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
MG1655(DE3) SEGA057
Species:Escherichia coli
Group:K12
Strain designation:MG1655(DE3)SEGA057
Accession number:LMBP 12893
Depositor:A.Ehrmann1 and Prof.Dr M.N?rholm1.It was constructed by C.Bayer1,A.Ehrmann1 and M.Rennig1.
1 The Novo Nordisk Foundation Center for Biosustainability,Technical University of Denmark,Horsholm,Denmark
Containment level:This strain has been assigned the containment level Class 1 following the European Directive 2009/41/EC on the contained use of genetically modified organisms,and its updates(see also the Belgian risk group classification).
Other culture collection numbers:SEGA 57
Medium:LB-Lennox
Selection marker:tetracycline(10μg/ml)
Temperature:28°C
Genotype:F-λ(DE3[lacI lacUV5-T7gene1 ind1 sam7 nin5])ilvG-rfb-50 rph-1 glmS-pstS::PT7-medium-BCD-gfp-tetA(Source:http://openwetware.org/wiki/E._coli_genotypes#MG1655+Bayer et al.,2021)
SEGA sequence:p12893.gb
Phenotype:tetR
Properties:The strain was created based on Escherichia coli K12 MG1655,by integrating the SEGA landing pad between the glmS and pstS loci.The strain contains DE3,aλprophage carrying the T7 RNA polymerase gene under control of the lac UV5 promoter and lacIq.IPTG is required to induce expression of the T7 RNA polymerase.Protein expression from transforming plasmids containing a T7 promoter-driven expression system is repressed until IPTG induction of T7 RNA polymerase expression occurs.
Further information:This host strain is intended for simplistic bacterial genome engineering,using the SEGA genome architecture.
Original reference:Bayer et al.,Nat.Commun.12(2021),5876[DOI:10.1038/s41467-021-26155-5]
Restricted use:-BCCM MTA
-The depositor will be informed of the customer's identity upon release of a sample outside the depositor's department.
Refer in your Materials and Methods:
Escherichia coli K12 MG1655(DE3)SEGA057(LMBP 12893)is available at BCCM/GeneCorner.It was deposited by A.Ehrmann and Prof.Dr M.N?rholm and was published in Bayer et al.,2021.
Group:K12
Strain designation:MG1655(DE3)SEGA057
Accession number:LMBP 12893
Depositor:A.Ehrmann1 and Prof.Dr M.N?rholm1.It was constructed by C.Bayer1,A.Ehrmann1 and M.Rennig1.
1 The Novo Nordisk Foundation Center for Biosustainability,Technical University of Denmark,Horsholm,Denmark
Containment level:This strain has been assigned the containment level Class 1 following the European Directive 2009/41/EC on the contained use of genetically modified organisms,and its updates(see also the Belgian risk group classification).
Other culture collection numbers:SEGA 57
Medium:LB-Lennox
Selection marker:tetracycline(10μg/ml)
Temperature:28°C
Genotype:F-λ(DE3[lacI lacUV5-T7gene1 ind1 sam7 nin5])ilvG-rfb-50 rph-1 glmS-pstS::PT7-medium-BCD-gfp-tetA(Source:http://openwetware.org/wiki/E._coli_genotypes#MG1655+Bayer et al.,2021)
SEGA sequence:p12893.gb
Phenotype:tetR
Properties:The strain was created based on Escherichia coli K12 MG1655,by integrating the SEGA landing pad between the glmS and pstS loci.The strain contains DE3,aλprophage carrying the T7 RNA polymerase gene under control of the lac UV5 promoter and lacIq.IPTG is required to induce expression of the T7 RNA polymerase.Protein expression from transforming plasmids containing a T7 promoter-driven expression system is repressed until IPTG induction of T7 RNA polymerase expression occurs.
Further information:This host strain is intended for simplistic bacterial genome engineering,using the SEGA genome architecture.
Original reference:Bayer et al.,Nat.Commun.12(2021),5876[DOI:10.1038/s41467-021-26155-5]
Restricted use:-BCCM MTA
-The depositor will be informed of the customer's identity upon release of a sample outside the depositor's department.
Refer in your Materials and Methods:
Escherichia coli K12 MG1655(DE3)SEGA057(LMBP 12893)is available at BCCM/GeneCorner.It was deposited by A.Ehrmann and Prof.Dr M.N?rholm and was published in Bayer et al.,2021.
